Lifestyles and cardiovascular risk in individuals with functional psychoses

Perspectives in Psychiatric Care

Volumn 45, Issue 2, 2009, Pages 87-99

  Fusar Poli, Paolo ^a   De Marco, Luca ^a   Cavallin, Francesca ^a   Bertorello, Andrea ^a   Nicolasi, Matteo ^a   Politi, Pierluigi ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Cardiovascular risk; Lifestyle; Prevention; Psychosis; Schizophrenia

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; ATTITUDE TO HEALTH; CARDIOVASCULAR DISEASE; COMORBIDITY; CROSS-SECTIONAL STUDY; DRINKING BEHAVIOR; EXERCISE; FEEDING BEHAVIOR; FEMALE; HEALTH BEHAVIOR; HEALTH SURVEY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ITALY; LIFESTYLE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NURSING; PSYCHOLOGICAL ASPECT; PSYCHOSIS; RISK FACTOR; SMOKING;

ADOLESCENT; ADULT; AGED; ALCOHOL DRINKING; CARDIOVASCULAR DISEASES; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; EXERCISE; FEMALE; FOOD HABITS; HEALTH BEHAVIOR; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SURVEYS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; ITALY; LIFE STYLE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PSYCHOTIC DISORDERS; RISK FACTORS; SMOKING; YOUNG ADULT;

EID: 63849329115     PISSN: 00315990     EISSN: 17446163     Source Type: Journal    
DOI: 10.1111/j.1744-6163.2009.00202.x     Document Type: Article

References (43)

1. Allison, D. B., Fontaine, K. R., Heo, M., Mentore, J. L., Cappelleri, J. C., Chandler, L. P., Weiden, P. J. Cheskin, L. J. (1999). The distribution of body mass index among individuals with and without schizophrenia. Journal of Clinical Psychiatry, 60, 215 220.
2. Barnett, A. H., Mackin, P., Chaudhry, I., Farooqi, A., Gadsby, R., Heald, A., et al 2007). Minimising metabolic and cardiovascular risk in schizophrenia: Diabetes, obesity and dyslipidaemia. Journal of Psychopharmacology, 21, 357 373.
3. Belleville, J. (2002). The French paradox: Possible involvement of ethanol in the protective effect against cardiovascular diseases. Nutrition, 18, 173 177.
4. Bellivier, F. (2005). Schizophrenia, antipsychotics and diabetes: Genetic aspects. European Psychiatry, 20 (Suppl 4 S335 S339.
5. Berglund, L. Anuurad, E. (2008). Role of lipoprotein(a) in cardiovascular disease current and future perspectives. Journal of the American College of Cardiologists, 52, 132 134.
6. Birkenaes, A. B., Sogaard, A. J., Engh, J. A., Jonsdottir, H., Ringen, P. A., Vaskinn, A., et al 2006). Sociodemographic characteristics and cardiovascular risk factors in patients with severe mental disorders compared with the general population. Journal of Clinical Psychiatry, 67, 425 433.
7. Brown, L. A., Cook, R. T., Jerrells, T. R., Kolls, J. K., Nagy, L. E., Szabo, G., et al 2006). Acute and chronic alcohol abuse modulate immunity. Alcoholism, Clinical and Experimental Research, 30, 1624 1631.
8. Clarke, M. C., Harley, M. Cannon, M. (2006). The role of obstetric events in schizophrenia. Schizophrenia Bulletin, 32, 3 8.
9. Cohn, T., Prud'homme, D., Streiner, D., Kameh, H. Remington, G. (2004). Characterizing coronary heart disease risk in chronic schizophrenia: High prevalence of the metabolic syndrome. Canadian Journal of Psychiatry, 49, 753 760.
10. de Lange, D. W. van de Wiel, A. (2004). Drink to prevent: Review on the cardioprotective mechanisms of alcohol and red wine polyphenols. Seminar of Vascular Medicine, 4, 173 186.
11. Dickerson, F. B., Brown, C. H., Kreyenbuhl, J. A., Fang, L., Goldberg, R. W., Wohlheiter, K. Dixon, L. B. (2006). Obesity among individuals with serious mental illness. Acta Psychiatrica Scandinavica, 113, 306 313.
12. Dinan, T. G. (2004). Stress and the genesis of diabetes mellitus in schizophrenia. British Journal of Psychiatry, 47 (Suppl S72 S75.
13. Drici, M. D. Priori, S. (2007). Cardiovascular risks of atypical antipsychotic drug treatment. Pharmacoepidemiology and Drug Safety, 16, 882 890.
14. Ebrahim, S., Beswick, A., Burke, M. Davey Smith, G. (2006). Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Systematic Reviews, Issue 4, Art. no. CD001561.
15. Filik, R., Sipos, A., Kehoe, P. G., Burns, T., Cooper, S. J., Stevens, H., et al 2006). The cardiovascular and respiratory health of people with schizophrenia. Acta Psychiatrica Scandinavica, 113, 298 305.
16. Ford, E. S., Giles, W. H. Dietz, W. H. (2002). Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. Journal of the American Medical Association, 287, 356 359.
17. George, T. P., Ziedonis, D. M., Feingold, A., Pepper, W. T., Satterburg, C. A., Winkel, J., et al 2000). Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. American Journal of Psychiatry, 157, 1835 1842.
18. Goff, D. C. (2007). Integrating general health care in private community psychiatry practice. Journal of Clinical Psychiatry, 68 (Suppl 4 49 54.
19. Goff, D. C., Cather, C., Evins, A. E., Henderson, D. C., Freudenreich, O., Copeland, P. M., et al 2005). Medical morbidity and mortality in schizophrenia: Guidelines for psychiatrists. Journal of Clinical Psychiatry, 66, 183 194 quiz 147, 273 274.
20. Heiskanen, T., Niskanen, L., Lyytikainen, R., Saarinen, P. I. Hintikka, J. (2003). Metabolic syndrome in patients with schizophrenia. Journal of Clinical Psychiatry, 64, 575 579.
21. Hennekens, C. H., Hennekens, A. R., Hollar, D. Casey, D. E. (2005). Schizophrenia and increased risks of cardiovascular disease. American Heart Journal, 150, 1115 1121.
22. Istituto Superiore di Sanità 2007, January 1). "Progetto Cuore" database. Retrieved September 15, 2008, from http://www.cuore.iss. it/eng/index-en.htm
23. Jones, M. Jones, A. (2008). The effect of antipsychotic medication on metabolic syndrome. Nursing Standard, 22, 43 48.
24. Kato, M. M., Currier, M. B., Gomez, C. M., Hall, L. Gonzalez-Blanco, M. (2004). Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. Primary Care Companion to the Journal Clinical Psychiatry, 6, 74 77.
25. Kearney, M., Bradbury, C., Ellahi, B., Hodgson, M. Thurston, M. (2005). Mainstreaming prevention: Prescribing fruit and vegetables as a brief intervention in primary care. Public Health, 119, 981 986.
26. Lambert, T. J., Velakoulis, D. Pantelis, C. (2003). Medical comorbidity in schizophrenia. Medical Journal of Australia, 178 (Suppl S67 S70.
27. McCreadie, R. G. (2003). Diet, smoking and cardiovascular risk in people with schizophrenia: Descriptive study. British Journal of Psychiatry, 183, 534 539.
28. McCreadie, R. G., Kelly, C., Connolly, M., Williams, S., Baxter, G., Lean, M. Paterson, J. R. (2005). Dietary improvement in people with schizophrenia: Randomised controlled trial. British Journal of Psychiatry, 187, 346 351.
29. Meyer, J., Koro, C. E. L'Italien, G. J. (2005). The metabolic syndrome and schizophrenia: A review. International Reviews in Psychiatry, 17, 173 180.
30. Morley, R. (2006). Fetal origins of adult disease. Seminars in Fetal Neonatal Medicine, 11, 73 78.
31. Muir-Cochrane, E. (2006). Medical co-morbidity risk factors and barriers to care for people with schizophrenia. Journal of Psychiatric Mental Health Nurses, 13, 447 452.
32. Newcomer, J. W. Haupt, D. W. (2006). The metabolic effects of antipsychotic medications. Canadian Journal of Psychiatry, 51, 480 491.
33. Newcomer, J. W. Hennekens, C. H. (2007). Severe mental illness and risk of cardiovascular disease. Journal of the American Medical Association, 298, 1794 1796.
34. Ninomiya, T. Kiyohara, Y. (2007). Albuminuria and chronic kidney disease in association with the metabolic syndrome. Journal of Cardiometabolic Syndrome, 2, 104 107.
35. Osby, U., Correia, N., Brandt, L., Ekbom, A. Sparen, P. (2000). Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophrenia Research, 45, 21 28.
36. Parekh, R. S. Klag, M. J. (2001). Alcohol: Role in the development of hypertension and end-stage renal disease. Current Opinion in Nephrology and Hypertension, 10, 385 390.
37. Pollmacher, T., Haack, M., Schuld, A., Kraus, T. Hinze-Selch, D. (2000). Effects of antipsychotic drugs on cytokine networks. Journal of Psychiatric Research, 34, 369 382.
38. Punnoose, S. Belgamwar, M. R. (2006). Nicotine for schizophrenia. Cochrane Database Systematic Reviews, Issue 1, Art. no. CD004838.
39. Rimm, E. B., Williams, P., Fosher, K., Criqui, M. Stampfer, M. J. (1999). Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. British Medical Journal, 319, 1523 1528.
40. Rohleder, N. Kirschbaum, C. (2006). The hypothalamic-pituitary-adrenal (HPA) axis in habitual smokers. International Journal of Psychophysiology, 59, 236 243.
41. Tsang, C., Higgins, S., Duthie, G. G., Duthie, S. J., Howie, M., Mullen, W., et al 2005). The influence of moderate red wine consumption on antioxidant status and indices of oxidative stress associated with CHD in healthy volunteers. British Journal of Nutrition, 93, 233 240.
42. Tutor-Crespo, M. J., Paz, E., Hermida, J. Tutor, J. C. (2007). Renal tubular dysfunction in schizophrenic patients treated with antipsychotic drugs. Clinical Laboratory, 53, 433 438.
43. Wang, Z., Nicholls, S. J., Rodriguez, E. R., Kummu, O., Horkko, S., Barnard, J., et al 2007). Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nature Medicine, 13, 1176 1184.